Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Politically, the US policy environment is shifting with potential impacts on business, including lower corporate ... therapies at its Lilly Seaport Innovation Center. Eli Lilly and Company ...

Stocks are pricey—but there are values to be had. Learn more about our panelists’ picks in this week’s Roundtable installment ...

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

The suit names 21 defendants, including some of the biggest names in pharmaceuticals and insurance: Eli Lilly and Company ...

A longtime pharmaceutical executive laments the woeful state of the industry and calls for new leadership to win back public trust ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...